A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 161
- Registration Number
- NCT01610336
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1147
- Registration Number
- NCT01610284
- Locations
- 🇺🇸
USC Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisCompCancerCtr (3), Los Angeles, California, United States
🇺🇸University of California at Los Angeles Dept. of UCLA, Los Angeles, California, United States
🇺🇸University of Miami Univ Miami 2, Miami, Florida, United States
Post Hematopoietic Stem Cell Transplantation
Phase 4
Completed
- Conditions
- Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT01610297
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
A Phase I Study of LFA102 in Japanese Patients
Phase 1
Completed
- Conditions
- Castration-resistant Prostate Cancer, Advanced Breast Cancer
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01610050
- Locations
- 🇯🇵
Novartis Investigative Site, Chuo-ku, Tokyo, Japan
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 335
- Registration Number
- NCT01609478
- Locations
- 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1215
- Registration Number
- NCT01610037
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01605981
- Locations
- 🇧🇷
Novartis Investigative Site, Sao Paulo, Brazil
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: NVA237 50 µg and indacaterol 150 µgDrug: Placebo to NVA237 and indacaterol 150 µg
- First Posted Date
- 2012-05-23
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 449
- Registration Number
- NCT01604278
- Locations
- 🇬🇧
Novartis Investigative Site, Wiltshire, United Kingdom
Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer
Phase 1
Completed
- Conditions
- Advanced HER2-positive Breast Cancer or Gastric Cancer
- Interventions
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT01602406
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
Human Urine Sample Collection for Alport Nephropathy Biomarker Studies
Terminated
- Conditions
- Alport Syndrome
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT01602835
© Copyright 2025. All Rights Reserved by MedPath